Ascendis Pharma A/S To Present At Upcoming Investor Conferences

COPENHAGEN, Denmark, May 8, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced plans to present at several upcoming investor conferences.

Ascendis Pharma logo




Event:

Bank of America Merrill Lynch 2015 Health Care Conference - Las Vegas, NV

Date:

Wednesday, May 13, 2015 

Time:

10:00 a.m. PDT / 1:00pm EDT



Event:

UBS Global Healthcare Conference - New York, NY

Date:

Wednesday, May 20, 2015 

Time:

8:30 a.m. EDT



Event:

Bioquity Europe - Vienna, Austria 

Date:

Wednesday, May 20, 2015 

Time:

11:00 a.m. CET / 5:00 a.m. EDT

Links to audio webcasts of the Bank of America Merrill Lynch 2015 Health Care Conference and the UBS Global Healthcare Conference will be posted to the Ascendis Pharma website at www.ascendispharma.com, and will be available until June 30, 2015.

About Ascendis Pharma A/S

Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of bestinclass therapeutics that address significant unmet medical needs.  The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug.   

The Ascendis Pharma pipeline includes TransCon Growth Hormone, a proprietary program that has completed a Phase 2 study in adults with growth hormone deficiency, or GHD.  Ascendis Pharma is currently conducting a Phase 2 study of TransCon Growth Hormone in children with GHD.  Ascendis Pharma is also developing its wholly-owned TransCon Treprostinil for the treatment of pulmonary arterial hypertension, or PAH. In addition to its proprietary programs, Ascendis Pharma has formed collaborations focused on leading products in large markets that are of strategic importance to its collaboration partners. These collaborations are with Sanofi in diabetes and Genentech in the field of ophthalmology.

Contact:

Investor contact:
Martin Auster, M.D.
Chief Business Officer
(650) 617-3403
ma@ascendispharma.com

Media contact:
Marion Janic
Rooney & Associates 
(212) 223-4017
mjanic@rooneyco.com 

Logo - http://photos.prnewswire.com/prnh/20150128/171828LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ascendis-pharma-as-to-present-at-upcoming-investor-conferences-300079441.html

SOURCE Ascendis Pharma A/S

Help employers find you! Check out all the jobs and post your resume.

Back to news